Results 61 to 70 of about 18,762 (211)

Risk of Herpes Zoster in Individuals on Biologics, DMARDS and/or Corticosteroids for Autoimmune Diseases:A Systematic Review and Meta-Analysis [PDF]

, 2016
Background: Studies examining the risk of herpes zoster (HZ) associated with immunosuppressants, such as biologics, non-biological disease modifying agents (nbDMARDs) or corticosteroids, have generated conflicting results.
Alarcón-Segovia, Bachelez, Bejarano, Bongartz, Braun, Brenner, Bresnihan, Cardiel, Che, Chen, Choy, Cohen, Cutolo, Dechartres, Dixon, Dixon, Dreiher, Egger, Emery, Emery, Fleischmann, Fleischmann, Furie, Furst, Galloway, Genovese, Genovese, Gupta, Gupta, Harpaz, Hayward, Higgins, Higgins, Hoes, Kameda, Kawai, Keystone, Kost, Kourbeti, Kremer, Kremer, Kremer, Kremer, Lal, Leonardi, Long, McDonald, Merrill, Moher, Moreland, Moutsopoulos, Nakajima, Nishimoto, Osterman, Oxman, Oxman, Papp, Pappas, Peto, Rutgeerts, Sampathkumar, Sandborn, Sandborn, Schiff, Schreiber, Segan, Shah, Singh, Smitten, Smolen, Smolen, Spittal, Strangfeld, Stroup, Sweeting, Takeuchi, Tanaka, Tanaka, van der Heijde, van Vollenhoven, Veetil, Weiner, Wells, Winthrop, Winthrop, Winthrop, Wolfe, Yamamoto, Yawn, Yawn, Youssef, Yun, Zhang, Zisman, Zorzela   +94 more
core   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside—a Comprehensive Review [PDF]

, 2016
Throughout life, bone is continuously remodelled. Bone is formed by osteoblasts, from mesenchymal origin, while osteoclasts induce bone resorption. This process is tightly regulated. During inflammation, several growth factors and cytokines are increased
Alves, C.H. (Celso Henrique), Colin, E.M. (Edgar), Farrell, E. (Eric), Lubberts, E.W. (Erik), Vis, M. (Marijn)   +4 more
core   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ‐Induced Diabetic Rats via AMPK/JAK–STAT Pathway Crosstalk

Endocrinology, Diabetes & Metabolism
Background Chronic inflammation is a critical factor contributing to diabetes complications. Baricitinib inhibits JAK–STAT signalling, which can contribute to an anti‐inflammatory effect.
Mostafa Allahyari, AbdolJalal Marjani, Marie Saghaeian Jazi, Mehrdad Jahanshahi   +3 more
doaj   +1 more source

Type I interferonopathies in pediatric rheumatology. [PDF]

, 2016
Defective regulation of type I interferon response is associated with severe inflammatory phenotypes and autoimmunity. Type I interferonopathies are a clinically heterogenic group of Mendelian diseases with a constitutive activation of this pathway that ...
Candotti, F., Caorsi, R., Gattorno, M., Picco, P., Volpi, S.   +4 more
core   +2 more sources

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

The burgeoning field of innate immune-mediated disease and autoinflammation. [PDF]

, 2016
Immune-mediated autoinflammatory diseases are occupying an increasingly prominent position among the pantheon of debilitating conditions that afflict mankind.
McDermott, MF, Peckham, D, Savic, S, Scambler, T   +3 more
core   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023

Dermatology and Therapy
Introduction Baricitinib is an oral selective Janus kinase 1/2 inhibitor approved for the treatment of the immune-mediated inflammatory skin diseases atopic dermatitis (AD) and alopecia areata (AA).
Julien Seneschal, lgnasi Figueras Nart, Silvia Sabatino, Manny Papadimitropoulos, Srishti Dabral, Anastasia Lampropoulou   +5 more
doaj   +1 more source